arrow_back Back Filing freshness 10-Q Q1 FY2025 SEC EDGAR

Traws Pharma, Inc.

TRAW
$0.55 ▼ -0.02 (-3.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Traws Pharma, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $5.9M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share $-0.24
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 5, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-7.11M
↑ +4.5%
Operating Margin Operating profit as % of sales
-45.7%
↑ +74.6%
FCF / Share Free cash flow per share
$-0.24
↑ +69.0%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of -1.98x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 58 quarters